Beatrice Manghisi

Monza, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

DNMT3A Co-Mutation and Real-World Clinical Outcomes With Gilteritinib in FLT3-Mutated Acute Myeloid Leukaemia Across Molecular Subgroups.

DNMT3A Co-Mutation and Real-World Clinical Outcomes With Gilteritinib in FLT3-Mutated Acute Myeloid Leukaemia Across Molecular Subgroups.

Journal: EJHaem
Published: July 14, 2026

Prognostic Score for Myelodysplastic Syndromes Based on Molecular Evolution.

Prognostic Score for Myelodysplastic Syndromes Based on Molecular Evolution.

Journal: NEJM evidence
Published: May 26, 2026

Unmet Needs and Their Impact on Quality of Life and Symptoms in Myelodysplastic Neoplasm Patients and Caregivers.

Unmet Needs and Their Impact on Quality of Life and Symptoms in Myelodysplastic Neoplasm Patients and Caregivers.

Journal: Cancers
Published: March 28, 2025

Case Report: Successful use of emapalumab in adult B-cell acute lymphoblastic leukemia experiencing severe neurotoxicity and hemophagocytic lymphohistiocytosis-like features after CAR-T cell therapy.

Case Report: Successful use of emapalumab in adult B-cell acute lymphoblastic leukemia experiencing severe neurotoxicity and hemophagocytic lymphohistiocytosis-like features after CAR-T cell therapy.

Journal: Frontiers in immunology
Published: January 20, 2025

Communicating the diagnosis of a hematological neoplastic disease to patients' minor children: a multicenter prospective study.

Communicating the diagnosis of a hematological neoplastic disease to patients' minor children: a multicenter prospective study.

Journal: The oncologist
Published: October 31, 2023

Idiopathic erythrocytosis: a germline disease?

Idiopathic erythrocytosis: a germline disease?

Journal: Clinical and experimental medicine
Published: August 29, 2023

First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis.

First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis.

Journal: Blood
Published: June 20, 2023

DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients.

DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients.

Journal: HemaSphere
Published: October 31, 2022

Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID-19 vaccine: A single-center prospective observational study (NCT05074706).

Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID-19 vaccine: A single-center prospective observational study (NCT05074706).

Journal: EJHaem
Published: June 16, 2022
Showing 1-9 of 9

Last Updated: 09/26/2026